The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Targeting the ERBB family in cancer: couples therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Self-citationCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I. J., & Hung, M.-C. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.015 · Cited by 490
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 471
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
The EGFRvIII variant in glioblastoma multiforme
Gan, H. K., Kaye, A. H., & Luwor, R. B. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.12.005 · Cited by 396
The ErbB/HER receptor protein-tyrosine kinases and cancer
Roskoski, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.150 · Cited by 395
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 390
Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A., Koutcher, J. A., Spassova, M., Ouerfelli, O., Mellinghoff, I. K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38746 · Cited by 368
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)
Huang, S., Armstrong, E. A., Benavente, S., Chinnaiyan, P., & Harari, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0562 · Cited by 366
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 349
Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0284 · Cited by 343
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Nuclear EGFR contributes to acquired resistance to cetuximab
Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L. (2009) · Oncogene · doi:10.1038/onc.2009.234 · Cited by 313
Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Tabernero, J., Guzmán, M., Rodriguez, S., Arribas, J., Palacios, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0870 · Cited by 277
The nuclear epidermal growth factor receptor signaling network and its role in cancer.
Brand, T. M., Iida, M., Li, C., & Wheeler, D. L. (2011) · PubMed · Cited by 266
Role of HER receptors family in development and differentiation
Casalini, P., Iorio, M. V., Galmozzi, E., & Ménard, S. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20007 · Cited by 246
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 240
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
E. Taylor, T., B. Furnari, F., & K. Cavenee, W. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277557 · Cited by 240
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Linardou, H., Dahabreh, I. J., Bafaloukos, D., Kosmidis, P., & Murray, S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 234
Schneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 222
Pedersen, M. W., Jacobsen, H. J., Koefoed, K., Hey, A., Pyke, C., Haurum, J. S., & Kragh, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1417 · Cited by 219
Self-citationWainberg, Z. A., Anghel, A., Desai, A. J., Ayala, R., Luo, T., Safran, B., Fejzo, M. S., Hecht, J. R., Slamon, D. J., & Finn, R. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1112 · Cited by 211
Bos, M., Mendelsohn, J. M., Kim, Y. M., Albanell, J., Fry, D. W., & Baselga, J. M. (1997) · PubMed · Cited by 199
Hegi, M. E., Diserens, A.-C., Bady, P., Kamoshima, Y., Kouwenhoven, M. C. M., Delorenzi, M., Lambiv, W. L., Hamou, M.-F., Matter, M. S., Koch, A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0048 · Cited by 194
Huang, W.-C., Chen, Y.-J., Li, L.-Y., Wei, Y.-L., Hsu, S.-C., Tsai, S.-L., Chiu, P.-C., Huang, W.-P., Wang, Y.-N., Chen, C.-H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240796 · Cited by 190
Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X., & Harari, P. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1611 · Cited by 188
Epidermal Growth Factor Receptor Translocation to the Mitochondria
Demory, M. L., Boerner, J. L., Davidson, R., Faust, W., Miyake, T., Lee, I., Hüttemann, M., Douglas, R., Haddad, G., & Parsons, S. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000760 · Cited by 184
Yamashita-Kashima, Y., Iijima, S., Yorozu, K., Furugaki, K., Kurasawa, M., Ohta, M., & Fujimoto-Ouchi, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2927 · Cited by 176
Heimberger, A. B., Learn, C. A., Archer, G. E., McLendon, R. E., Chewning, T. A., Tuck, F. L., Pracyk, J. B., Friedman, A. H., Friedman, H. S., Bigner, D. D., et al. (2002) · PubMed · Cited by 169
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
Reid, A. H. M., Vidal, L., Shaw, H. M., & Bono, J. S. D. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.007 · Cited by 168
Schmidt, M. H. H., Furnari, F. B., Cavenee, W. K., & Bögler, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031790100 · Cited by 164
Spangler, J. B., Neil, J. R., Abramovitch, S., Yarden, Y., White, F. M., Lauffenburger, D. A., & Wittrup, K. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913476107 · Cited by 161
Janjigian, Y. Y., Groen, H. J. M., Horn, L., Smit, E. F., Fu, Y., Wang, F., Shahidi, M., Denis, L. J., Pao, W. J., & Miller, V. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7525 · Cited by 145
Johns, T. G., Adams, T. E., Cochran, J. R., Hall, N. E., Hoyne, P. A., Olsen, M. J., Kim, Y., Rothacker, J., Nice, E. C., Walker, F., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401218200 · Cited by 144
Self-citationThe ErbB receptor tyrosine family as signal integrators.
Hynes, N. E., Horsch, K., Olayioye, M. A., & Badache, A. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080151 · Cited by 142
CETUXIMAB: From Bench to Bedside
Vincenzi, B., Zoccoli, A., Pantano, F., Venditti, O., & Galluzzo, S. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910790980241 · Cited by 141
Role of ErbB4 in Breast Cancer
Sundvall, M., Iljin, K., Kilpinen, S. K., Sara, H., Kallioniemi, O., & Elenius, K. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9079-3 · Cited by 138
Janjigian, Y. Y., Azzoli, C. G., Krug, L. M., Pereira, L. K., Rizvi, N. A., Pietanza, M. C., Kris, M. G., Ginsberg, M. S., Pao, W. J., Miller, V. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2662 · Cited by 126
Weickhardt, A. J., Price, T. J., Chong, G., Gebski, V., Pavlakis, N., Johns, T. G., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6599 · Cited by 115
Self-citationBria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A. J., Scagliotti, G. V., Cognetti, F., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq742 · Cited by 111
Jimeno, A., Rubio‐Viqueira, B., Amador, M. L., Oppenheimer, D., Bouraoud, N., Kulesza, P., Sebastiani, V., Maitra, A., & Hidalgo, M. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3586 · Cited by 110
Gan, H. K., Walker, F., Burgess, A. W., Rigopoulos, A., Scott, A. M., & Johns, T. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605136200 · Cited by 108
Self-citationDual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Garrett, J. T., Sutton, C. R., Kuba, M. G., Cook, R. S., & Arteaga, C. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2024 · Cited by 108
Perera, R. M., Narita, Y., Furnari, F. B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2653 · Cited by 103
Johns, T. G., Luwor, R. B., Murone, C., Walker, F., Weinstock, J., Vitali, A. A., Perera, R. M., Jungbluth, A. A., Stockert, E., Old, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036503100 · Cited by 99
Self-citationTargeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Yoshida, T., Zhang, G., & Haura, E. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.014 · Cited by 97
ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor
Alvarado, D., Klein, D. E., & Lemmon, M. A. (2009) · Nature · doi:10.1038/nature08297 · Cited by 92
Interaction of antibodies with ErbB receptor extracellular regions
Schmitz, K. R., & Ferguson, K. M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.008 · Cited by 91
Schaefer, G., Shao, L., Tótpál, K., & Akita, R. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3493 · Cited by 87
Rimawi, M. F., Wiechmann, L., Wang, Y.-C., Huang, C., Migliaccio, I., Wu, M.-F., Gutiérrez, C., Hilsenbeck, S. G., Arpino, G., Massarweh, S. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1905 · Cited by 87
Zhang, Q., Park, E., Kani, K., & Landgraf, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200105109 · Cited by 80
Small Molecules with EGFR-TK Inhibitor Activity
Albanell, J., & Gascón, P. (2005) · Current Drug Targets · doi:10.2174/1389450053765888 · Cited by 70
Zhu, H., Cao, X., Ali‐Osman, F., Keir, S. T., & Lo, H. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.01.028 · Cited by 70
Dong, J., Demarest, S. J., Sereno, A., Tamraz, S., Langley, E. J., Doern, A., Snipas, T., Perron, K., Joseph, I. B. J., Glaser, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1018 · Cited by 68
Spicer, J. F., & Rudman, S. M. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0140-y · Cited by 62
Ramalingam, S. S., Forster, J., Naret, C., Evans, T. L., Sulecki, M., Lu, H., Teegarden, P., Weber, M. R., & Belani, C. P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181653d1b · Cited by 54
Cvrljevic, A. N., Akhavan, D., Wu, M., Martinello, P., Furnari, F. B., Johnston, A. J., Guo, D., Pike, L. S., Cavenee, W. K., Scott, A. M., et al. (2011) · Journal of Cell Science · doi:10.1242/jcs.083295 · Cited by 51
Self-citationWang, Q., Li, S.-H., Wang, H., Xiao, Y. Q., Şahin, Ö., Brady, S. W., Li, P., Ge, H., Jaffee, E. M., Muller, W. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1339-t · Cited by 45
Cavazzoni, A., Alfieri, R. R., Cretella, D., Saccani, F., Ampollini, L., Galetti, M., Quaini, F., Graiani, G., Madeddu, D., Mozzoni, P., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-91 · Cited by 44
Manzari, M. T., Rosalia, E. K., Chen, T. F., Wittrup, K. D., & Spangler, J. B. (2012) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 39
Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin
Xu, S., & Weihua, Z. (2011) · The Prostate · doi:10.1002/pros.21337 · Cited by 26
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
The MAPK pathway across different malignancies: A new perspective
Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C. (2014) · Cancer · doi:10.1002/cncr.28864 · Cited by 956
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., van Bergen en Henegouwen, P. M. P., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 625
Metadata
- Authors
- Tebbutt, N., Pedersen, M. W., & Johns, T. G.
- Venue
- Nature Reviews Cancer
- Published
- 2013-08-16
- Volume
- 13
- Issue
- 9
- Pages
- 663-673
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2005202092
- Cited by
- 466
- References
- 83
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.